Cheap stocks can be a smart choice for investors, as there are serious bargains to be found. The stocks below may be cheap, but they all have significant support from Wall Street’s best-performing analysts. To pinpoint these top stocks, we turned to  TipRanks’ unique stock screener. We used this screener, which covers over 5,000 stocks, to find only the best stocks with a ‘Strong Buy’ analyst consensus rating. This is based on all the ratings that a stock has received in the last three months alone. From the results, we quickly scanned for stocks trading at under $10, while also looking for those with compelling analyst price targets. Most of the stocks listed below are small-cap or micro-cap stocks, but as one analyst says “For those who can look small, this could be big.”

Here are five cheap stocks from top analysts that we believe are worth tracking into 2018:

1. Seres Therapeutics (Nasdaq:MCRB)

Seres is a top stock to track right now according to the Street. The company is working on treating infectious and inflammatory diseases by adding ‘good’ bacteria to your digestive tract. According to analysts, its lead product candidate, SER-109 (made up of microbial spores) could revolutionize the treatment of diseases like inflammatory bowel disease.

“We rate Seres Outperform with a $19 12- to 18-month price target, based on our conviction that multiple programs in the company’s pipeline can achieve regulatory and commercial success” writes Oppenheimer analyst Mark Breidenbach on November 8. Given that the stock is now trading at just $9.54, his price target suggests potential upside of just under 100 percent from the current share price.

Additionally, Breidenbach is looking out for two trial results expected in early 2018- including top-line results from the ongoing Phase 1b trial of SER-262. This is the company’s microbial restoration therapy for primary CDI recurrence (C. difficile infection). Overall, MCRB has received only buy ratings from the Street in the last three months. Based on the price target of five analysts, the stock has a bullish average analyst price target of $18.7.